On Tuesday 23 January, the European Commission announced changes regarding In Vitro Diagnostic Medical Devices Regulation (IVDR).
The release states, “the European Commission is proposing more time for companies to apply the In Vitro Diagnostic Medical Devices Regulation (IVDR), under certain conditions. With this revision, the Commission aims to ensure patient care by improving the availability of these essential healthcare products. The Commission is also proposing measures to enhance transparency in the Medical Device sector including by speeding up the launch of some elements of the European Database on Medical Devices – EUDAMED”.
The full proposal will now be put forward to the European Parliament and Council for adoption.
Secondly, the proposal aims to enable a gradual roll-out of the electronic systems integrated into the European database on medical devices (EUDAMED) that are finalised, instead of deferring the mandatory use of EUDAMED until the last of the six modules is completed.
What are the new timelines?
Under the measures announced, the additional time granted to companies depends on the type of device:
- high individual and public health risk devices such as HIV or hepatitis tests (class D) would have a transition period until 31 December 2027;
- high individual and/or moderate public health risk devices such as cancer tests (class C), would have a transition period until 31 December 2028;
- lower risk devices (class B such as pregnancy tests and class A sterile devices such as blood collection tubes), have a transition period until 31 December 2029.
Barcoding success bitesize
Explore our range of short introductory videos on how to accurately barcode your products.
Verify your barcodes
We can check your barcodes to ensure they are GS1 compliant and can be scanned at the point of care.